Spyre Therapeutics, Inc. (SYRE) Earnings
|
Expand Research on SYRE
| Next EPS Date | 11/5/26 | EPS Growth Rate | -406.7% |
|---|---|---|---|
| Average EPS % Beat Rate | +37.8% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +3.4% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/5/26  |
Q326 | N/A | -$0.76 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 8/4/26 |
Q226 | -$0.36 | -$0.76 | +$0.40 | N/A | N/A | N/A |  | | Details | |
| 5/5/26 |
Q126 | -$0.74 | -$0.67 | -$0.07 | N/A | N/A | N/A | | | Details | |
| 2/26/26 |
Q425 | N/A | -$0.70 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 11/4/25 |
Q325 | -$0.15 | -$0.77 | +$0.62 | N/A | N/A | N/A | | | Details | |
| 8/5/25 |
Q225 | N/A | -$0.75 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 8/4/25 |
Q225 | N/A | -$0.75 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 8/1/25 |
Q225 | N/A | -$0.75 | N/A | N/A | N/A | N/A | N/A | N/A |
